Peer Review reports
From: Use of Bevacizumab in recurrent glioblastoma: a scoping review and evidence map
| Original Submission | ||
|---|---|---|
| 27 Jan 2023 | Submitted | Original manuscript |
| 13 Mar 2023 | Reviewed | Reviewer Report |
| 16 Mar 2023 | Reviewed | Reviewer Report |
| 27 Mar 2023 | Reviewed | Reviewer Report |
| 6 Apr 2023 | Author responded | Author comments - Wei Hua |
| Resubmission - Version 2 | ||
| 6 Apr 2023 | Submitted | Manuscript version 2 |
| 12 Apr 2023 | Reviewed | Reviewer Report |
| 21 Apr 2023 | Reviewed | Reviewer Report |
| 22 Apr 2023 | Reviewed | Reviewer Report |
| 15 May 2023 | Author responded | Author comments - Wei Hua |
| Resubmission - Version 3 | ||
| 15 May 2023 | Submitted | Manuscript version 3 |
| 16 May 2023 | Author responded | Author comments - Wei Hua |
| Resubmission - Version 4 | ||
| 16 May 2023 | Submitted | Manuscript version 4 |
| 5 Jun 2023 | Reviewed | Reviewer Report |
| Resubmission - Version 5 | ||
| Submitted | Manuscript version 5 | |
| Publishing | ||
| 6 Jun 2023 | Editorially accepted | |
| 14 Jun 2023 | Article published | 10.1186/s12885-023-11043-6 |
You can find further information about peer review here.